{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:57:39Z","timestamp":1781254659342,"version":"3.54.1"},"reference-count":73,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Benzodiazepine receptor agonists (BZRA) are frequently tapered because of risk of dependence and hazards of use in ageing. Standard tapering protocols may fail or result in harm from improper utilization of pharmacologic principles, lack of recognition of withdrawal and\/or failures in shared decision-making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The aim of this work was to derive principles from experts to optimize deprescribing success while minimizing withdrawal among patients who use BZRA medication long-term.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Modified Delphi consensus study among experts from two not-for-profit organizations dedicated to BZRA use issues.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Three stages of anonymized voting were conducted among clinical experts and patient representatives. An 80% agreement (\u2018agree\u2019 or \u2018strongly agree\u2019 on a five item Likert-type scale) was required for consensus. Recommendations which failed to reach initial consensus, were modified from feedback and downgraded to \u2018moderate\u2019 (&gt;80% agreement) or \u2018weak\u2019 consensus (50%\u201380% agreement) in the subsequent rounds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 35 of 48 invitees participated (73% response rate) which included seven family physicians, nine psychiatrists, five pharmacists, six patient advocates, two nurse practitioners, two licensed clinical social workers, two health service policy researchers, a physician assistant and a psychotherapist. A total of 31 of 35 participants were from the United States, with the remaining representatives from Canada, the UK and Ireland. Strong consensus was achieved for attaining informed consent prior to deprescribing (recommendation 1), using a flexible and gradual tapering approach (recommendation 2) characterized by shared decision-making (recommendation 3) with hyperbolic dose reductions (recommendation 4) facilitated via novel preparation techniques or compounded pharmaceutical formulations (recommendation 7). Reversion to previous doses may occur if necessary to reduce the incidence of withdrawal (recommendation 6). Strong consensus was also reached for adjunctive psychosocial interventions (recommendation 8) and\/or peer-support resources (recommendation 9). Moderate and weak consensus was achieved, respectively, for step-wise conversion to a longer-acting BZRA (recommendation 5) and the avoidance of adjunctive non-BZRA pharmacotherapy (recommendation 10).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This consensus guidance document for primary care providers, mental health clinicians and long-term users of BZRA outlines ten principles\/recommendations intended for improving deprescribing outcomes with an emphasis on minimizing withdrawal risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20451253261457547","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T03:57:27Z","timestamp":1781063847000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Benzodiazepine receptor agonist deprescribing principles for long-term use and dependence: modified Delphi recommendations from a multi-disciplinary expert panel"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4571-1079","authenticated-orcid":false,"given":"Jaden","family":"Brandt","sequence":"first","affiliation":[{"name":"Alliance for Benzodiazepine Best Practices, Portland, OR, USA"},{"name":"College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, 750 McDermot Ave., Winnipeg, MB R3E 0T5, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lamberson","sequence":"additional","affiliation":[{"name":"Benzodiazepine Information Coalition, Venice, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene","family":"Bressi","sequence":"additional","affiliation":[{"name":"Alliance for Benzodiazepine Best Practices, Portland, OR, USA"},{"name":"School of Public Health, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Ritvo","sequence":"additional","affiliation":[{"name":"Alliance for Benzodiazepine Best Practices, Portland, OR, USA"},{"name":"Psychiatry, University of Colorado Anschutz, Anschutz Medical Campus, Aurora, CO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Curle","sequence":"additional","affiliation":[{"name":"Benzodiazepine Information Coalition, Venice, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Witt-Doerring","sequence":"additional","affiliation":[{"name":"Benzodiazepine Information Coalition, Venice, FL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"DeWert","sequence":"additional","affiliation":[{"name":"Alliance for Benzodiazepine Best Practices, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Wright","sequence":"additional","affiliation":[{"name":"Alliance for Benzodiazepine Best Practices, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1318-2029","authenticated-orcid":false,"given":"Mark","family":"Horowitz","sequence":"additional","affiliation":[{"name":"North East London NHS Foundation Trust, Research and Development, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2011.01.002"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2013.538"},{"key":"e_1_3_4_4_2","article-title":"Zopiclone: a review of its pharmacological properties and therapeutic efficacy as an hypnotic","volume":"3","author":"Wadworth AN","year":"1993","unstructured":"Wadworth AN, McTavish D. Zopiclone: a review of its pharmacological properties and therapeutic efficacy as an hypnotic. Drugs Aging 1993; 3: 441\u201359.","journal-title":"Drugs Aging"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2011.11.003"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2012.04418.x"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-017-0207-7"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102507"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsad124"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1159\/000525207"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.2020.164"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1192\/bja.2022.62"},{"issue":"2","key":"e_1_3_4_13_2","first-page":"167","article-title":"Benzodiazepine dependence and withdrawal: identification and medical management","volume":"5","author":"Landry MJ","year":"1992","unstructured":"Landry MJ, Smith DE, McDuff DR, et al. Benzodiazepine dependence and withdrawal: identification and medical management. J Am Board Fam Pract 1992; 5(2): 167\u2013176.","journal-title":"J Am Board Fam Pract"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2011.03563.x"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1715050"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01206-7"},{"key":"e_1_3_4_17_2","article-title":"\u2018We need more support and doctors that understand the process of tapering . . .\u2019: a content analysis of free-text responses to a questionnaire on discontinuing long-term benzodiazepine receptor agonist use","volume":"27","author":"Lynch T","year":"2024","unstructured":"Lynch T, Ryan C, Huff C, et al. \u2018We need more support and doctors that understand the process of tapering . . .\u2019: a content analysis of free-text responses to a questionnaire on discontinuing long-term benzodiazepine receptor agonist use. Heal Expect 2024; 27: 1\u201311.","journal-title":"Heal Expect"},{"issue":"5","key":"e_1_3_4_18_2","first-page":"339","article-title":"Deprescribing benzodiazepine receptor agonists","volume":"64","author":"Pottie K","year":"2018","unstructured":"Pottie K, Thompson W, Davies S, et al. Deprescribing benzodiazepine receptor agonists. Can Fam Physician 2018; 64(5): 339\u2013351.","journal-title":"Can Fam Physician"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2022.1150"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285584"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcpt.13333"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02445-4"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30032-X"},{"key":"e_1_3_4_24_2","first-page":"1","article-title":"Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators?","author":"Vinkers CH","year":"2012","unstructured":"Vinkers CH, Olivier B. Mechanisms underlying tolerance after long-term benzodiazepine use: a future for subtype-selective GABAA receptor modulators? Adv Pharmacol Sci 2012: 1\u201319.","journal-title":"Adv Pharmacol Sci"},{"key":"e_1_3_4_25_2","first-page":"28","volume-title":"The Maudsley deprescribing guidelines: antidepressants, benzodiazepines, gabapentinoids and Z-drugs","author":"Horowitz MA","year":"2024","unstructured":"Horowitz MA, Taylor D. The neurobiology of tapering. In: The Maudsley deprescribing guidelines: antidepressants, benzodiazepines, gabapentinoids and Z-drugs. Hoboken, NJ; West Sussex, UK: Wiley Blackwell, 2024, pp. 28\u201335."},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.5770\/cgj.23.419"},{"key":"e_1_3_4_27_2","unstructured":"National Institute for Clinical Excellence. Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults [NG215] 2022. https:\/\/www.nice.org.uk\/guidance\/ng215"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-025-09499-2"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221082386"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253221145561"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088266"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43586-023-00214-1"},{"key":"e_1_3_4_33_2","first-page":"297","volume-title":"The Maudsley deprescribing guidelines: antidepressants, benzodiazepines, gabapentinoids and Z-drugs","author":"Horowitz MA","year":"2024","unstructured":"Horowitz MA, Taylor D. Safe deprescribing of benzodiazepines and Z-drugs. In: The Maudsley deprescribing guidelines: antidepressants, benzodiazepines, gabapentinoids and Z-drugs. 1st ed. Hoboken, NJ; West Sussex, UK: Wiley Blackwell, 2024, pp. 297\u2013361.","edition":"1"},{"key":"e_1_3_4_34_2","unstructured":"Ashton H. Benzodiazepines: how they work and how to withdraw. 3rd ed. Benzodiazepine Information Coalition 2002 pp. 1\u201396. https:\/\/www.benzoinfo.com\/wp-content\/uploads\/2022\/07\/Ashton-Manual.pdf"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780197517277.001.0001"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000524400"},{"issue":"102","key":"e_1_3_4_37_2","first-page":"1","article-title":"Use of Delphi in health sciences research","volume":"7","author":"Shang Z.","year":"2023","unstructured":"Shang Z. Use of Delphi in health sciences research. Medicine (Baltimore) 2023; 7(102): 1\u20137.","journal-title":"Medicine (Baltimore)"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326"},{"key":"e_1_3_4_39_2","unstructured":"Howick J Chalmers I Glasziou P et al. The 2011 Oxford CEBM Levels of Evidence: Introductory Document. Oxford Centre for Evidence Based Medicine 2011 pp. 1\u20133."},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhrm.21200"},{"key":"e_1_3_4_41_2","unstructured":"Huff C Wright S. Benzodiazepine Information Coalition https:\/\/www.benzoinfo.com\/informed-consent\/ (2021 accessed 19 Feb 2022)."},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6424.1135"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1994.tb03743.x"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharma.2009.07.001"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02364.x"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0397-8"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.033"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-021-01285-w"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01061774"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001131"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp16X683485"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198610023151403"},{"key":"e_1_3_4_53_2","first-page":"498","article-title":"Tapering off long-term benzodiazepine use with or without group cognitive ^ behavioural therapy : three-condition, randomised controlled trial","volume":"182","author":"Oude Voshaar RC","year":"2003","unstructured":"Oude Voshaar RC, Gorgels WJMJ, Mol AJJ, et al. Tapering off long-term benzodiazepine use with or without group cognitive ^ behavioural therapy : three-condition, randomised controlled trial. Br J Pharmacol 2003; 182: 498\u2013505.","journal-title":"Br J Pharmacol"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231171518"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph15091091"},{"issue":"5","key":"e_1_3_4_56_2","article-title":"Psychosocial interventions for benzodiazepine harmful use, abuse or dependence","volume":"5","author":"Darker CD","year":"2015","unstructured":"Darker CD, Sweeney BP, Barry JM, et al. Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. Cochrane Database Syst Rev 2015; 5(5): CD009652.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/pcn.13195"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2019.101214"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1558\/cam.22677"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/hex.13392"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2018.04.028"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-015-0019-8"},{"issue":"3","key":"e_1_3_4_63_2","article-title":"Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users","volume":"3","author":"Baandrup L","year":"2018","unstructured":"Baandrup L, Ebdrup BH, Rasmussen J\u00d8, et al. Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. Cochrane database Syst Rev 2018; 3(3): CD011481.","journal-title":"Cochrane database Syst Rev"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1177\/2045125317753340"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.01973.x"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115537"},{"key":"e_1_3_4_67_2","first-page":"1","article-title":"A systematic review of manipulations to pharmaceutical dosage forms used in psychotropic tapering plans","author":"O\u2019Brien D","year":"2025","unstructured":"O\u2019Brien D, Healy AM, Harkin A, et al. A systematic review of manipulations to pharmaceutical dosage forms used in psychotropic tapering plans. Br J Clin Pharmacol 2025; (November 2024): 1\u201315.","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.48557"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2015.07.006"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1694"},{"key":"e_1_3_4_71_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2024.5020"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.2217\/pgs-2022-0161"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-03048-y"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-022-00960-y"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261457547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20451253261457547","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20451253261457547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:16:22Z","timestamp":1781252182000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20451253261457547"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":73,"alternative-id":["10.1177\/20451253261457547"],"URL":"https:\/\/doi.org\/10.1177\/20451253261457547","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6951221\/v1","asserted-by":"object"}]},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"20451253261457547"}}